| 📌 The essentials On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia (denosumab, Amgen) for all five of Prolia’s approved indications. Commercial launch expected Q3 2026. This is the 19th FDA-approved denosumab biosimilar, not the first. Several have already launched commercially in the United States with modest savings of approximately 5 to 15% below Prolia’s list price. Critical distinction for patients: PONLIMSI is approved as a biosimilar but does NOT have interchangeable designation. Only Jubbonti (Sandoz) has interchangeable status for Prolia, meaning only Jubbonti can be substituted by a pharmacist without calling your prescriber. Simultaneously, Teva announced that the FDA and EMA have both accepted regulatory filings for its proposed omalizumab (Xolair) biosimilar. This is not an approval; it is the start of review. A Prolia discontinuation warning: do not stop denosumab abruptly for any reason, including a transition to a biosimilar. Rebound vertebral fractures are a documented serious risk. Any transition must be clinician-guided. |
|---|
Osteoporosis affects an estimated 200 million people globally and is responsible for approximately 9 million fractures per year worldwide. In the United States, about 10 million adults have osteoporosis and another 44 million have low bone density, putting them at elevated fracture risk. Hip fractures in older adults carry a one-year mortality rate of up to 36%, a statistic that makes bone health a genuine life-or-death clinical priority, not a cosmetic concern.
Denosumab (Prolia, Amgen) is one of the most effective medications available for high-risk osteoporosis. It reduces vertebral fracture risk by up to 68%, hip fractures by 40%, and nonvertebral fractures by 20% in clinical trials. It is also, without insurance, a $2,506 injection administered twice a year, making it inaccessible or unaffordable for many of the patients who need it most.
On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, and simultaneously announced that regulatory agencies in both the U.S. and Europe have accepted filings for its proposed biosimilar to Xolair (omalizumab), a biologic used in severe asthma, nasal polyps, and IgE-mediated food allergy. These are meaningful regulatory events, but they exist in a context that the original announcement does not capture: the denosumab biosimilar market is now crowded, savings to patients have been disappointingly modest so far, and understanding the difference between a biosimilar and an interchangeable biosimilar has real implications for whether your pharmacist can make the switch without calling your doctor.
What Denosumab Does and Why It Is So Expensive
Denosumab is a fully human monoclonal antibody that works by inhibiting RANKL, receptor activator of nuclear factor kappa-B ligand, a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for breaking down bone. By blocking RANKL, denosumab suppresses bone resorption, which allows bone mineral density to increase and fracture risk to fall.
Amgen markets denosumab under two brand names: Prolia (60 mg subcutaneous injection every 6 months) for osteoporosis and bone loss from hormonal cancer therapies, and Xgeva (120 mg every 4 weeks) for preventing skeletal-related events in patients with bone metastases and giant cell tumors. The two products use the same molecule but are approved for different indications at different doses.
The $2,500+ price per dose reflects the cost of biologic drug manufacturing. Denosumab is produced in living cells using complex, expensive processes, not synthesized chemically like a small molecule tablet. Amgen has generated approximately $2.9 billion annually from Prolia alone. Despite recent patent expirations in the U.S. and Europe opening the door to biosimilar competition, the denosumab market has yet to see the dramatic price reductions that biosimilar proponents hoped for.
| A critical clinical nuance: the rebound fracture risk on discontinuation Denosumab has a well-documented risk of rebound vertebral fractures when treatment is stopped abruptly. Because denosumab’s anti-resorptive effect reverses quickly after the drug clears the system, faster than bisphosphonates which accumulate in bone tissue, stopping denosumab without transitioning to another therapy can produce a rapid spike in bone turnover that significantly increases fracture risk in the first 12 to 24 months after discontinuation. Multiple cases of simultaneous vertebral fractures following denosumab discontinuation have been reported in the literature. Current guidelines recommend that patients stopping denosumab for any reason, including switching to a biosimilar if the transition is not managed carefully, receive bridging therapy with a bisphosphonate. This is not a biosimilar-specific concern, but it is relevant for any patient or prescriber navigating a formulary switch or change in product. |
|---|
PONLIMSI: What the Approval Is Based On
PONLIMSI (denosumab-adet) received FDA approval on March 30, 2026, based on a totality of evidence demonstrating comparable efficacy, safety, and immunogenicity to Prolia. This evidence includes data from a randomized, double-blind Phase 3 clinical trial (NCT04729621) enrolling 332 women with postmenopausal osteoporosis, comparing denosumab-adet directly against Prolia across these endpoints.
PONLIMSI is approved for all five indications of the reference product Prolia:
| Indication | Patient Population |
|---|---|
| Postmenopausal osteoporosis | Women at high risk for fracture, including history of fracture or multiple risk factors; or failed or intolerant to other osteoporosis therapy |
| Male osteoporosis | Men at high risk for fracture |
| Glucocorticoid-induced osteoporosis | Men and women on long-term corticosteroid therapy at high risk for fracture |
| Prostate cancer bone loss | Men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer |
| Breast cancer bone loss | Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer |
The EMA granted marketing authorization for PONLIMSI in Europe in November 2025, meaning the drug had already been approved in the EU before its U.S. clearance. Teva has indicated a commercial launch in the United States is expected in Q3 2026.
The Critical Distinction: Biosimilar vs. Interchangeable and Why It Matters for Patients
This is the most practically important piece of information in this post, and it was absent from the original coverage of PONLIMSI’s approval.
In the United States, there are two categories of FDA-approved biosimilars: biosimilar and interchangeable biosimilar. The difference matters at the pharmacy counter.
| Biosimilar | Interchangeable Biosimilar | |
|---|---|---|
| FDA standard | Highly similar to reference product; no clinically meaningful differences in safety, purity, potency | Same as biosimilar PLUS: can be substituted without the prescriber’s involvement |
| Pharmacy substitution | Cannot be substituted automatically; requires prescriber authorization or new prescription in most states | Can be substituted by pharmacist without calling the prescriber (subject to state pharmacy laws) |
| Benefit to payer and patient | May require step therapy or prior authorization to access lower cost | Formulary substitution can happen more easily, driving faster cost competition |
| PONLIMSI status | Biosimilar only, NOT interchangeable (as of approval) | Jubbonti (Sandoz) has interchangeable designation |
| Real-world implication | Prescriber or insurer action typically needed | Pharmacist can swap without a call to the prescriber |
Teva’s announcement did not mention an interchangeability designation for PONLIMSI. This means that in most U.S. states, a pharmacist cannot automatically substitute PONLIMSI for Prolia based on a prescription for denosumab. A clinician or insurer action is typically required. Patients who want to access the biosimilar version may need to ask their provider to write a new prescription specifically for PONLIMSI, or navigate a formulary preference process through their insurer.
The Denosumab Biosimilar Landscape: 19 Approvals, Modest Savings
PONLIMSI is not entering an empty market. By the time it launches in Q3 2026, it will be one of at least 19 FDA-approved denosumab biosimilars. Eighteen were approved by the end of December 2025, with PONLIMSI the first addition in 2026. Several have already launched commercially in the United States.
| Biosimilar | Company | FDA Status | Notes |
|---|---|---|---|
| Jubbonti / Wyost | Sandoz | Approved March 2024; launched June 2025 | First to market; interchangeable designation; 14.5% below Prolia WAC |
| Osenvelt / Stoboclo | Celltrion | Launched July 2025 | 5 to 10% discount range reported |
| Jubereq / Osvyrti | Accord BioPharma | Launched October 2025 | Competitive pricing |
| Enoby / Xtrenbo | Gedeon Richter / Hikma | Approved; not yet launched | — |
| Bilprevda / Bildyos | Henlius / Organon | Approved; not yet launched | — |
| PONLIMSI | Teva | Approved March 2026; Q3 2026 launch expected | No interchangeability designation announced |
The savings picture has been a disappointment relative to earlier expectations. Sandoz’s Jubbonti, the first approved interchangeable denosumab biosimilar, launched in June 2025 at a list price approximately 14.5% below Prolia’s wholesale acquisition cost. Celltrion’s biosimilars entered at an estimated 5 to 10% discount. A published budget impact model in the Journal of Medical Economics projected savings of $0.59 per member per month for health plans at medium conversion rates over five years, meaningful at scale, but not the 50 to 80% price reductions that biosimilar competition drove in markets like Europe.
| Why are U.S. denosumab biosimilar savings so modest compared to Europe? In the UK, biosimilar adoption within the first year of launch routinely exceeds 90% of market share, driven by NHS tender-based procurement and institutional formulary switches. British rheumatologist Dr. Muhammad Nisar noted to Medscape that clinicians feel very comfortable with denosumab biosimilars, with great belief in their efficacy and safety. In the U.S., the market structure is fundamentally different. Amgen has kept Prolia competitively priced through rebates to pharmacy benefit managers (PBMs) and insurers. The net price paid by many payers may already be below the biosimilar list price after rebates. This perverse dynamic, in which originator rebates can make a brand-name drug cheaper to a payer than the biosimilar list price, is a structural feature of the U.S. drug market that dampens biosimilar adoption and competition. The interchangeability designation matters here too. Only Sandoz’s Jubbonti has interchangeable status for Prolia, allowing direct pharmacy substitution. The other approved denosumab biosimilars, including PONLIMSI, require prescriber action or payer-directed formulary changes to reach patients, slowing the pace of market conversion. |
|---|
The Xolair Biosimilar Filing: A Different Market, A Different Opportunity
Teva’s simultaneous announcement that both the FDA and EMA have accepted filings for its proposed biosimilar to Xolair (omalizumab, Genentech/Novartis) is a separate and strategically distinct event from the PONLIMSI approval.
What omalizumab is and who uses it
Omalizumab (Xolair) is a monoclonal antibody that works by binding to free IgE, immunoglobulin E, the antibody class central to allergic responses, and blocking its interaction with IgE receptors on mast cells and basophils. By reducing free IgE levels, omalizumab prevents the downstream allergic cascade that produces symptoms in atopic disease.
Xolair is approved in the U.S. for: moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids in patients 6 and older whose asthma is related to a perennial allergen; chronic rhinosinusitis with nasal polyps in adults; chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by antihistamines; and IgE-mediated food allergies in patients 1 year and older. That food allergy indication, the most recent addition, significantly expanded the patient population that might use omalizumab.
The market context
Global omalizumab sales are estimated at $3.5 to $3.7 billion annually, making this a commercially meaningful biosimilar target. Regulatory filing acceptance by both FDA and EMA simultaneously means Teva’s submission was complete enough for substantive review. This is not an approval; it is the beginning of the regulatory review process. The FDA’s standard review clock for biosimilar applications is 12 months from acceptance.
The omalizumab biosimilar market is at an earlier stage than denosumab. The omalizumab biosimilar landscape will be watched carefully by allergists, pulmonologists, and patients with severe allergic disease who currently pay thousands of dollars per year for brand-name Xolair, a cost that is a meaningful access barrier for many.
What This Means in Practice: Guidance for Patients
If you are currently on Prolia or another denosumab product
Do not stop denosumab without a medical plan for what comes next. The rebound fracture risk on discontinuation is real and serious. Any transition to a biosimilar should be clinician-guided, maintaining the same dosing schedule (every 6 months for Prolia indications) and likely incorporating a bisphosphonate bridge if you stop denosumab for any reason.
If cost is a barrier to accessing denosumab, ask your prescriber or pharmacist specifically about available biosimilar options. If your insurer’s formulary includes an interchangeable denosumab biosimilar like Jubbonti, your pharmacist may be able to substitute automatically. For non-interchangeable biosimilars like PONLIMSI, a prescriber action is required. Medicare Part B, through which administered biologics are often covered, has specific biosimilar substitution rules worth understanding with your provider.
If you are on Xolair for allergic asthma, nasal polyps, urticaria, or food allergy
A biosimilar is not yet available. Teva’s application is under review, and even after approval, launch timing will depend on regulatory processes and commercial decisions. Continue your current treatment as prescribed. Monitor your insurer’s formulary for updates in 2026 and 2027.
The Gap Between Biosimilar Approval and Patient Savings
The denosumab biosimilar story is instructive for understanding how U.S. drug pricing actually works and why regulatory approval of a biosimilar does not automatically translate to patient savings.
When Prolia’s key patents began expiring, the expectation was that biosimilar competition would drive meaningful price reductions, as it has in Europe. Instead, 19 FDA approvals later, the most aggressive biosimilar discount achieved is about 14.5% below Prolia’s list price. The originator still commands most of the market. The structural reasons are complex: Amgen’s rebate practices, the lack of interchangeability designation for most competitors, the physician-administered nature of the injection (which keeps it under Part B rather than Part D, with different substitution rules), and the clinical hesitancy around switching patients who have been stable on a therapy that must not be interrupted without a plan.
Flanigan et al. noted in their 2025 Journal of Medical Economics budget impact analysis that even a small discount of 5% for a biosimilar referencing Xgeva and Prolia could represent millions of dollars in savings for a health plan, with the potential for reinvestment to further expand access. Those savings are real at scale even when they feel modest at the individual patient level.
None of this means biosimilar approvals like PONLIMSI are without value. For payers, even modest per-dose discounts multiply across large patient populations. For patients in countries with less fragmented pricing structures, competitive biosimilar availability is genuinely transformative. And building a competitive biosimilar market, however slowly, creates the foundation for the price competition that patients deserve.
The omalizumab filing, if it leads to approval and launch, enters a somewhat less saturated biosimilar market. The recent addition of the food allergy indication has expanded the potential patient population substantially. That approval, if and when it comes, may be a more commercially differentiated moment than PONLIMSI in the already crowded denosumab space.
For related coverage of how access and affordability are shaping the drug landscape in 2026, see our post on FDA approval of the first generic dapagliflozin, where a similar story of high list prices, biosimilar or generic entry, and the gap between approval and real-world savings is unfolding in the type 2 diabetes space.
Sources
Clinical Advisor coverage: FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review. clinicaladvisor.com. April 2026.
Drug Topics: FDA Approves Denosumab-Adet as Biosimilar to Prolia. drugtopics.com. March 2026.
Center for Biosimilars: FDA Approves Teva Biosimilar for Denosumab in Osteoporosis. centerforbiosimilars.com. March 2026.
GaBI Online: FDA approves denosumab biosimilar Ponlimsi. gabionline.net. April 2026.
Medscape: Two More Denosumab Biosimilars Approved in the US. medscape.com. October 2025.
Managed Healthcare Executive: Biosimilar denosumab could save $0.59 per member per month. managedhealthcareexecutive.com. February 2026.
Journal of Medical Economics budget impact: Flanigan J, Chaplin S, et al. A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ. 2025;28(1):2027-2038. doi:10.1080/13696998.2025.2027-2038.
PONLIMSI Phase 3 trial: NCT04729621. ClinicalTrials.gov.
GoodRx pricing: How Much Is Prolia Without Insurance? goodrx.com.
Rebound fracture risk: Rebound vertebral fractures after denosumab discontinuation. PMC6683162.
Denosumab mechanism: Denosumab. StatPearls. NCBI.
RANKL biology: RANKL in bone biology. PMC3386061.
Hip fracture mortality: Hip fracture 1-year mortality. PMC6530614.
FDA biosimilars explained: Biosimilar and Interchangeable Products. FDA.gov.
FDA approved biosimilar products: FDA-Approved Biosimilar Products. FDA.gov.
Prolia FDA approval: FDA approves denosumab for osteoporosis. FDA.gov.
Xgeva FDA approval: FDA approves denosumab (Xgeva). FDA.gov.
Xolair FDA approval: FDA approves omalizumab for allergic asthma. FDA.gov.
IgE biology: IgE in allergy. StatPearls. NCBI.
PBM market structure: Pharmacy Benefit Managers. PMC7748166.
Bisphosphonates: Bisphosphonates. StatPearls. NCBI.
Patient resources: Bone Health and Osteoporosis Foundation | FDA Biosimilar Products List | GoodRx Prolia pricing
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about denosumab therapy, including switching between reference products and biosimilars, should be made in consultation with a qualified prescriber familiar with the patient’s bone health history and fracture risk. Never discontinue denosumab without medical guidance. |
|---|
Leave a Reply